New faculty promotion and tenure guidelines take into account efforts in technology commercialization. The move is a cultural shift that emphasizes developing ideas with the potential to benefit the local and state economy, and beyond. Continue reading
Category Archives: Members
AZBIO Member Guest Posts
Keeping AZ BioTalent in AZ
A letter to AZBio Members – A Guest Post on UA Career ServicesContinue reading
Make your mark as part of the TGen CLIA Lab Team
Position Available in the DCL Lab at the Translational Genomics Research Institute Continue reading
SynCardia to expand with $19M in new financing
SynCardia Secures $19M Financing for Total Artificial Heart
$15M Financed by Athyrium Opportunities Fund, $4M by Existing ShareholdersContinue reading
Apply to be a TGen Helios Scholar
The Translational Genomics Research Institute (TGen) is pleased to announce the 2013 application opening for the Helios Scholars paid summer internship program in biomedical research!Continue reading
Stimwave joins BioInspire Incubator
BioAccel Adds Stimwave Technologies To BioInspire Medical Device Incubator. Stimwave Becomes Sixth Company in 3 months to join the BioInspire Incubator Model Moving Innovations to Commercialization for ArizonaContinue reading
UA Cancer Center – Phoenix Project Approved for Construction
The Arizona Board of Regents has given final project approval for construction of The University of Arizona Cancer Center – Phoenix outpatient clinic at the Phoenix Biomedical Campus.Continue reading
Partners work together to accelerate development of new treatments for multiple sclerosis
The National Multiple Sclerosis Society and Critical Path Institute Create the Multiple Sclerosis Outcome Assessments ConsortiumContinue reading
RiboMed Receives Three Additional Patents for Disease Diagnostics Methods
RiboMed Biotechnologies Inc., a leading Epigenetics-Based Diagnostics company, today announced that the U.S. Patent and Trademark Office has issued three additional patents covering the use of their core technology, Abscription® (Abortive Transcription), for disease and biowarfare agent related biomarker detection. The patents expand protection to MethylMagnet® and MethylMeter®, RiboMed’s bisulfite-free DNA methylation detection products and assays, including a new prognostic test for brain cancer, G-CIMP DecisionDx. Continue reading